Name | Lankacidin C |
---|---|
Synonyms |
Bundlin A
(-)-lankacidin C Antibiotic T-2636C N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-Dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxopropanamide lankacidins Lankacidin |
Description | Lankacidin C is an inhibitor of protein synthesis in vitro. Lankacidin C inhibits the activity of L1210 leukemia, B16 melanoma and 6C3 HED/OG lymphosarcoma cell lines. Lankacidin C has antibacterial activity and antitumor activity[1][2]. |
---|---|
Related Catalog | |
In Vivo | Lankacidin C (75-1000 mg/kg;腹腔注射;一天一次持续 5 天) 以剂量依赖性方式延长了 (C57BL/6×DBA/2) F1 (BDF1) 小鼠的平均生存时间。Lankacidin C (1000 mg/kg) 在植入 B-16 黑色素瘤的 C57BL/6 小鼠中显著抑制了 B-16 黑色素瘤的生长[2]。 Lankacidin C (300 mg/kg;腹腔注射;一天一次持续 6 天) 在含有L-1210/6-巯基嘌呤或 L-1210/阿糖胞苷的 BDF1 小鼠中,抑制对 6-巯基嘌呤 (6-Mercaptopurine,HY-13677) 或阿糖胞苷 (Cytosine Arabinoside,HY-13605) 耐药的 L-1210 细胞活性[2]。 Lankacidin C (10-100 mg/kg;腹腔注射;一天一次持续 5 天) 显著延长了含有 6C3 HED/OG 或 6C3 HED/RG 淋巴肉瘤的 C3H/He 小鼠平均生存时间[2]。 Lankacidin C (500 mg/kg;腹腔注射;一天一次持续 3 或 4 天) 在抗原刺激前后抑制 ICR 小鼠抗绵羊红细胞抗体的产生[2]。 Animal Model: C57BL/6, C3H/He, ICR and (C57BL/6×DBA/2) F1 (BDF1) mice[2]. Dosage: 10, 20, 25, 30, 40, 50, 100, 150, 250, 300, 500, 600 or 1000 mg/kg Administration: Intraperitoneal injection; once daily for 3, 4, 5 or 6 days Result: Inhibited the growth of L1210 leukemia, B16 melanoma and 6C3 HED/OG or 6C3 HED/RG lymphosarcoma cells. |
References |
Density | 1.23g/cm3 |
---|---|
Molecular Formula | C25H33NO7 |
Molecular Weight | 459.53200 |
Exact Mass | 459.22600 |
PSA | 130.00000 |
LogP | 2.10860 |
Index of Refraction | 1.566 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
~% 23623-31-6 |
Literature: Kakinuma, Katsumi; Uzawa, Jun; Uramoto, Masakazu Tetrahedron Letters, 1982 , vol. 23, # 50 p. 5303 - 5306 |
Precursor 1 | |
---|---|
DownStream 0 |